Melanoma-associated antigen 12 (MAGE-A12) (MAGE-A12)

Melanoma-associated antigen 12 (MAGE-A12) is a member of the MAGE-A subfamily of cancer-testis antigens, characterized by its restricted expression in immune-privileged tissues like the testis and its aberrant expression in various malignancies [UniProt P43366]. Biologically, MAGE-A12 is thought to function as a scaffold for E3 ubiquitin ligases, such as TRIM28, thereby regulating protein degradation pathways that influence cell cycle progression and apoptosis [Doyle et al., 2010]. In the context of oncology, it serves as a promising target for T-cell receptor (TCR) engineered T-cell therapies and cancer vaccines due to its high tumor specificity [Lin et al., 2011]. However, MAGE-A12 gained significant clinical notoriety when a TCR-T therapy targeting MAGE-A3 caused fatal neurotoxicity because of unexpected MAGE-A12 expression in the human brain, specifically the thalamus and hypothalamus [Morgan et al., 2013]. This event highlighted the critical need for rigorous screening of off-tumor expression in the central nervous system for MAGE-family targets. Current therapeutic strategies focus on developing highly specific TCRs that can distinguish MAGE-A12 from other family members or avoid brain-expressed epitopes to ensure safety [Lin et al., 2011].

Other names

MAGE12Cancer/testis antigen 1.12CT1.12Melanoma antigen family A 12

T-cell receptor (TCR) mediated recognition of HLA-presented peptides leading to cytotoxic T-lymphocyte activation [Morgan et al., 2013].